Regen Biopharma Inc. Initiates Small Molecule Hit Validation Study On Cancer Stem Cell Target Gene

Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today that it has initiated studies for its small molecule drug discovery platform on its cancer stem cell target gene. These studies are expected to be completed within the next two months.

[Read the full article here]

Comments are closed.